Vildagliptine Sustained Release Tablets 100 mg – Vildos 100 Sr Tablets

Vildos 100 SR Tablets
Composition:- Vildagliptin 100 mg (Sustained Release)

Vildos 100 SR Tablets – Vildagliptin 100 mg SR (Sustained Release) Tablets is an oral antidiabetic medication belonging to the DPP-4 inhibitor class, specifically designed for the management of type 2 diabetes mellitus. By enhancing the activity of incretin hormones, Vildagliptin stimulates insulin secretion when blood glucose levels are elevated while simultaneously suppressing glucagon release. This dual action helps to effectively lower blood glucose levels and maintain glycemic control.

Key Points of Vildagliptine Sustained Release Tablets 100 mg – Vildos 100 Sr Tablets

• Selective DPP-4 Inhibition: Vildagliptin selectively inhibits the DPP-4 enzyme, increasing levels of incretin hormones (GLP-1 and GIP) which enhance insulin secretion in a glucose-dependent manner and decrease glucagon release.
• Comprehensive Glycemic Control: Effective in managing both fasting and postprandial blood glucose levels, making it suitable for a wide range of type 2 diabetes patients.
• Well-tolerated: Vildagliptin has a favorable side effect profile with a low incidence of gastrointestinal issues and no significant weight gain, making it a suitable option for patients concerned about weight.

• Diabetologist
• General Physician
• Endocrinologist
• Geriatrics
• Healthcare practitioner